Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 135.31 M
The data is delayed by 15 minutes.
CARA is in the long-term up 151% in 5 years.
Description: Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Its lead product candidate includes intravenous CR845, which has completed Phase II clinical trials for the treatment acute postoperative pain in adult patients. The company is also developing Oral CR845 that has completed Phase I clinical trial for the treatment of moderate-to-severe acute and chronic pain; and CR701, which is in preclinical trial for treating neuropathic and inflammatory pain. Cara Therapeutics, Inc. was founded in 2004 and is based in Shelton, Connecticut.
|Shares Outstanding||27.28 M||EPS||-2.52||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-49.06%||Sales Growth - Q/Q||-46.5%||P/E||-6.79|
|P/E To EPS Growth||P/S||38.79||P/BV||2.85||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-36.88%||ROE||-40.17%||ROI|
|Current Ratio||14.31||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.07|
|Gross Margin||Operating Margin||-555.3%||Net Profit Margin||-546.19%||Dividend Payout Ratio|
|Cash From Financing Activities||10 K||Cash From Investing Activities||-10 K||Cash From Operating Activities||-5.24 M||Gross Profit|
|Net Profit||-4.69 M||Operating Profit||-4.72 M||Total Assets||51.65 M||Total Current Assets||49.06 M|
|Total Current Liabilities||3.43 M||Total Debt||800 K||Total Liabilities||4.23 M||Total Revenue||490 K|
|High 52 week||23.95||Low 52 week||11.6||Last close||19.03||Last change||-0.68%|
|RSI||46.55||Average true range||0.99||Beta||1.6||Volume||1.26 M|
|Simple moving average 20 days||0.06%||Simple moving average 50 days||0.02%||Simple moving average 200 days||4.44%|
|Performance Week||1.17%||Performance Month||5.31%||Performance Quart||11.61%||Performance Half||0.69%|
|Performance Year||53.47%||Performance Year-to-date||46.38%||Volatility daily||2.89%||Volatility weekly||6.46%|
|Volatility monthly||13.24%||Volatility yearly||45.87%||Relative Volume||252.99%||Average Volume||692.03 K|
|New High||New Low|
2019-12-06 16:01:10 | Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan
2019-12-04 10:02:03 | Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More
2019-12-04 07:14:09 | Investors Who Bought Cara Therapeutics NASDAQ:CARA Shares Three Years Ago Are Now Up 78%
2019-12-03 16:01:10 | Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
2019-11-18 13:03:03 | Top Marijuana Stocks for November 2019
2019-11-13 09:12:02 | Is the Options Market Predicting a Spike in Cara Therapeutics CARA Stock?
2019-11-12 16:01:00 | Cara Therapeutics to Present at November Investor Conferences
2019-11-06 04:08:22 | Edited Transcript of CARA earnings conference call or presentation 5-Nov-19 9:30pm GMT
2019-11-05 18:35:11 | Cara Therapeutics CARA Reports Q3 Loss, Tops Revenue Estimates
2019-11-05 16:01:00 | Cara Therapeutics Reports Third Quarter 2019 Financial Results
2019-11-01 07:00:05 | Cara Therapeutics Announces Presentations at Kidney Week 2019
2019-10-29 16:01:05 | Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019
2019-10-28 19:55:55 | Here’s What Hedge Funds Think About Casa Therapeutics Inc CARA
2019-10-20 08:45:42 | Have Insiders Been Selling Cara Therapeutics, Inc. NASDAQ:CARA Shares?
2019-10-14 07:00:00 | Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
2019-10-01 14:23:51 | First cannabis cafe in the U.S. opens in Los Angeles
2019-09-26 16:01:00 | Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
2019-09-19 10:11:28 | How Much Of Cara Therapeutics, Inc. NASDAQ:CARA Do Institutions Own?
2019-08-21 16:24:33 | Cara Therapeutics Inc CARA Q2 2019 Earnings Call Transcript
2019-08-21 11:44:43 | 10 Marijuana Stocks That Could See 100% Gains, If Not More
2019-08-19 12:34:11 | Does Cara Therapeutics, Inc.'s NASDAQ:CARA CEO Pay Reflect Performance?
2019-08-08 05:37:56 | Edited Transcript of CARA earnings conference call or presentation 7-Aug-19 8:30pm GMT
2019-08-05 10:21:00 | Here's Why Cara Therapeutics Rose 11.3% in July
2019-08-05 07:21:00 | Only These 9 Cannabis Stocks Rose in July
2019-07-31 16:01:00 | Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019
2019-07-26 21:18:00 | Weekly Cannabis Stock News: Auxly's Surprise Strategic Partner Investment
2019-07-25 11:59:00 | Cara Therapeutics Floats New Stock Issue
2019-07-24 20:42:45 | Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock
2019-07-24 16:01:00 | Cara Therapeutics Announces Proposed Offering of Common Stock
2019-07-22 07:00:00 | Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment
2019-07-16 10:28:34 | 4 ‘Strong Buy’ Biotechs With Big 3Q19 Catalysts
2019-07-14 07:30:00 | 3 Top Biotech Stocks to Buy for the 2nd Half of 2019
2019-07-13 07:56:07 | Estimating The Fair Value Of Cara Therapeutics, Inc. NASDAQ:CARA
2019-07-12 18:27:33 | GuruFocus Value Idea Contest Sees 2 Winners!
2019-07-11 08:30:00 | Enteris BioPharma's _Feasibility-to-Licensing_ Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis
2019-07-02 07:16:00 | Better Buy: GW Pharmaceuticals vs. Cara Therapeutics
2019-06-02 09:09:00 | Is Cara Therapeutics a Buy Now?
2019-05-31 07:00:00 | Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference
2019-05-30 07:48:11 | Cara Shares Up on Positive Phase III Data for Itchiness Drug